APA (7th ed.) Citation

MT, K., J, M., AM, K., MCM, K., S, Z., K, G., & NWCJ, v. d. D. (2026). Balancing Efficacy and Safety in Multiple Myeloma Patients Receiving B cell Maturation Antigen-Directed CAR T-Cell Therapy. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 40(4), 607. https://doi.org/10.1007/s40259-026-00784-y

Chicago Style (17th ed.) Citation

MT, Kuipers, Migchelbrink J, Kramer AM, Kouwenhoven MCM, Zweegman S, Groen K, and van de Donk NWCJ. "Balancing Efficacy and Safety in Multiple Myeloma Patients Receiving B Cell Maturation Antigen-Directed CAR T-Cell Therapy." BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy 40, no. 4 (2026): 607. https://doi.org/10.1007/s40259-026-00784-y.

MLA (9th ed.) Citation

MT, Kuipers, et al. "Balancing Efficacy and Safety in Multiple Myeloma Patients Receiving B Cell Maturation Antigen-Directed CAR T-Cell Therapy." BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy, vol. 40, no. 4, 2026, p. 607, https://doi.org/10.1007/s40259-026-00784-y.